Reduced morbidity and mortality in the first year after initiating highly active anti-retroviral therapy (HAART) among ugandan adults

Tropical Medicine and International Health

Volumn 14, Issue 5, 2009, Pages 556-563

  Miiro, George ^a   Todd, Jim ^a,b   Mpendo, Juliet ^a   Watera, Christine ^a   Munderi, Paula ^a   Nakubulwa, Susan ^a   Kaddu, Ismael ^a   Rutebarika, Diana ^a   Grosskurth, Heiner ^a,b  

^a MRC/UVRI Uganda Research   (Uganda)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Adverse events; Cotrimoxazole prophylaxis; Highly active anti retroviral therapy; Morbidity

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RIFAMPICIN; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ANTIBIOTICS; BASELINE SURVEY; BLOOD; COHORT ANALYSIS; DISEASE TREATMENT; MORBIDITY; MORTALITY; REGRESSION ANALYSIS; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; DEPRESSION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PNEUMOCYSTIS PNEUMONIA; PSYCHOSIS; RASH; TREATMENT OUTCOME; UGANDA;

ADULT; AGED; ANTI-INFECTIVE AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; UGANDA; YOUNG ADULT;

AFRICA; EAST AFRICA; SUB-SAHARAN AFRICA; UGANDA;

EID: 65649102219     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2009.02259.x     Document Type: Article

References (35)

1. Autran B, Carcelaint G, Li TS et al. (1999) Restoration of the immune system with antiretroviral therapy. Immunology Letters 66, 207 211. (Pubitemid 29136840)
2. Badri M, Wilson D Wood R (2002) Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 359, 2059 2064. (Pubitemid 34680968)
3. Bonnet F, Thiebaut R, Chene G et al. (2005) Determinants of clinical progression in antiretroviral-naïve HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002. HIV Medicine 6, 198 205. (Pubitemid 40740337)
4. Bourboulia D, Aldam D, Lagos D et al. (2004) Short-and long-term effects of highly active antiretroviral therapy on Kaposi's sarcoma-associated herpesvirus immune responses and viraemia. AIDS 18, 485 493. (Pubitemid 38365876)
5. Brink AK, Mahe C, Watera C et al. (2002) CD4 counts and enteric infections in a community-based cohort of HIV-infected adults in Uganda. Journal of Infection 45, 99 106. (Pubitemid 36104822)
6. Brinkhof MW, Egger M, Boulle A et al. (2007) Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clinical Infectious Diseases 45, 1518 1521.
7. Brown M, Miiro G, Nkurunziza P et al. (2006) Schistosoma mansoni, nematode infections and progression to active tuberculosis among HIV-1-infected Ugandans. American Journal of Tropical Medicine and Hygiene 20, 1391 1399. (Pubitemid 46774403)
8. Coetzee D, Hildebrand K, Boulle A et al. (2004) Outcomes after 2 years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 18, 887 895. (Pubitemid 38553709)
9. Egger M, Hirschel B, Francioli P et al. (1997) Impact of new antiretroviral therapy in HIV infected patients in Switzerland: prospective multicentre study. BMJ 315, 1194 1199. (Pubitemid 27478210)
10. Fairall LR, Bachmann MO, Louwagie GM et al. (2008) Effectiveness of antiretroviral treatment in a South African program: a cohort study. Archives of Internal Medicine 168, 86 93.
11. Fielden SJ, Rusch ML, Levy AR et al. (2008) Predicting hospitalization among HIV-infected antiretroviral naïve patients starting HAART: Determining clinical markers and exploring social pathways. AIDS Care 20, 297 303.
12. Forna F, Liechty CA, Solberg P et al. (2007) Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. Journal of Acquired Immune Deficiency Syndromes 44, 456 462. (Pubitemid 46555382)
13. French N, Nakiyingi J, Carpenter LM et al. (2000) 23-valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: double blind, randomized and placebo controlled trial. Lancet 355, 2106 2111. (Pubitemid 30364659)
14. Gona P, Van Dyke RB, Williams PL et al. (2006) Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA 296, 292 300. (Pubitemid 44079313)
15. Hardon AP, Akurut D, Comoro C et al. (2007) Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care 19, 658 665. (Pubitemid 46763738)
16. Hung CC, Hsieh SM, Hsiao CF et al. (2001) Risk of recurrent non-typhoid Salmonella bacteraemia after early discontinuation of ciprofloxacin as secondary prophylaxis in AIDS patients in the era of highly active antiretroviral therapy. AIDS 15, 645 647. (Pubitemid 32281362)
17. Manzardo C, Zaccarelli M, Aguero F, Antinori A Miro JM (2007) Optimal timing and best antiretroviral regimen in treatment-naïve HIV-infected individuals with advanced disease. Journal of Acquired Immune Deficiency Syndromes 46, S9 S18. (Pubitemid 47312321)
18. Meiderma F, Danner SA, Schellekens PT et al. (1997) Patterns of T cell repopulation, viral load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents. Journal of Acquired Immune Deficiency Syndromes 16, 318 326. (Pubitemid 127730201)
19. Mermin J, Ekwaru JP, Liechty CA et al. (2006) Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet 367, 1256 1261.
20. Mermin J, Were W, Ekwaru JP et al. (2008) Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study. Lancet 371, 752 759.
21. Mocroft A, Katlama C, Johnson AM et al. (2000) AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 356, 291 296. (Pubitemid 30459587)
22. Moh R, Danel C, Sorho S et al. (2005) Haematological changes in adults receiving a Zidovudine-containing HAART regimen in combination with cotrimoxazole in Cote d'Ivoire. Antiviral Therapy 10, 615 624. (Pubitemid 41224953)
23. Morgan D, Mahe C, Okongo JM, Mayanja B Whitworth JA (2001) Genital ulceration in rural Uganda: sexual activity, treatment-seeking behaviour and the implications for HIV control. STD 28, 431 436.
24. Pape JW (1988) Treatment of gastrointestinal infections. AIDS 2 (Suppl 1 161 167. (Pubitemid 19042853)
25. Patella FJ, Delaney KM, Moorman AC et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. The New England Journal of Medicine 338, 853 860. (Pubitemid 28135961)
26. Pozio E (2004) Highly Active AntiRetroviral Therapy and opportunistic protozoan infections. Parassitologia 46, 89 93. (Pubitemid 40063855)
27. Sow PS, Otieno LF, Bissagnene E et al. (2007) Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries. Journal of Acquired Immune Deficiency Syndromes 44, 262 267. (Pubitemid 46328341)
28. Ssali F, Stohr W, Munderi P et al. (2006) Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. Antiviral Therapy 11, 741 749. (Pubitemid 44497169)
29. Subbaraman R, Chaguturu SK, Mayer KH, Flanigan TP Kumarasamy N (2007) Adverse effects of highly active antiretroviral therapy in developing countries. Clinical Infectious Disease 45, 1093 1101. (Pubitemid 47580363)
30. Thera MA, Sehdev PS, Coulibay D et al. (2005) Impact of trimethoprim-sulfamethoxazole propgylaxis on falciparum malaria infection and disease. The Journal of Infectious Diseases 192, 1823 1829. (Pubitemid 41587836)
31. Tumbarello M, Tacconella E, de Gaetano Donati K et al. (2000) HIV-associated bacteraemia: how it has changed in the highly active antiretroviral therapy (HAART) era. Journal of Acquired Immune Deficiency Syndromes 23, 145 151. (Pubitemid 30316839)
32. Verdier RI, Fitzergerald DW, Johnson WD Pape JW (2000) Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients. A randomized, controlled trial. Annals Internal Medicine 132, 885 888. (Pubitemid 30346851)
33. Watera C, Todd J, Muwonge R et al. (2006) Feasibility and effectiveness of cotrimoxazole prophylaxis for HIV-1-infected adults attending an HIV/AIDS clinic in Uganda. Journal of Acquired Immune Deficiency Syndromes 42, 373 378. (Pubitemid 44050018)
34. Watera C, Todd J, Mutonyi G et al. (2007) Effects of cotrimoxazole prophylaxis on haematological parameters in HIV infected adults in a community-based clinic in Entebbe, Uganda. Journal of Acquired Immune Deficiency Syndromes 46, 369 371. (Pubitemid 350287368)
35. WHO (1993) Proposed 'World Health Organization staging system for HIV infection and disease': preliminary testing by an international collaborative cross-sectional study. AIDS 7, 711 718. (Pubitemid 23204966)